Dennis Fenton

Dennis M.
Fenton founded Fenton & Associates LLC, where he is working as Chief Executive Officer.
Dr. Fenton also currently works at Cirius Therapeutics, Inc., as Chairman, Synedgen, Inc., as Director from 2021, The Scripps Research Institute, as Director, Omniox, Inc., as Director, Modern Meadow, Inc., as Director, First Tracks Biotherapeutics, Inc., as Independent Director, and Keck Graduate Institute of Applied Life Sciences, as Trustee.
Dr. Fenton also formerly worked at Dendreon Corp., as Independent Director from 2011 to 2015, Genzyme Corp., as Director from 2010 to 2011, Hospira, Inc., as Independent Director from 2012 to 2015, Napo Pharmaceuticals, Inc., as Director from 2011 to 2012, Genelux Corp., as Director, Amira Pharmaceuticals, Inc., as Director, Kythera Biopharmaceuticals LLC, as Lead Independent Director from 2012 to 2015, Biotechnology Innovation Organization, as Director, XenoPort, Inc., as Independent Director from 2011 to 2016, Nora Therapeutics, Inc., as Director, Pelican, Inc., as Independent Director from 2015 to 2019, Abzena Ltd., as Director, Portola Pharmaceuticals LLC, as Independent Director from 2015 to 2020, Sienna Biopharmaceuticals, Inc., as Independent Director from 2016 to 2019, AnaptysBio, Inc., as Independent Director from 2018 to 2026, Amgen, Inc., as Executive Vice President from 2000 to 2008, Pfizer Inc., as Senior Research Scientist, Rutgers State University of New Jersey, as Research Associate, Amgen Ventures LLC, as Executive Vice President-Operations from 2000 to 2007, and The Biotechnology Institute, as Trustee.
Dr. Fenton received his doctorate degree in 1977 from Rutgers State University of New Jersey and undergraduate degree in 1973 from Manhattan University.